Astra, UK charity hunt new kind of cancer drug
London: AstraZeneca has struck a deal with the commercial arm of a British charity to try and develop a new class of a "cancer metabolism" drugs.
The aim is to exploit the fact cancer cells use energy differently to normal cells, by creating new drugs that control cell metabolism in order to attack tumors whilst sparing normal tissues, the two partners said Sunday.
The three-year alliance will work on a portfolio of projects selected by Cancer Research UK`s commercialization and development arm, Cancer Research Technology (CRT).
AstraZeneca will take the most promising projects into pre-clinical and clinical drug development, sharing the risks and potential rewards with CRT.